Fixed-Dose HIV Therapy Reducing Drug Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV infection require combination regimens, leading to potential drug interactions and challenges in adherence, especially for patients with limited access to healthcare. Additionally, the HIV virus's propensity to mutate necessitates effective treatments across various viral variants.
Innovation Solution
Development of 2,3-dihydro-1H-pyrido[2,1-f][1,2,4]triazine compounds and their pharmaceutical compositions, which are designed to inhibit HIV replication with a reduced potential for drug interactions and improved pharmacokinetic properties for better patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination antiretroviral therapy regimens are used to suppress HIV, then viral suppression effectiveness is improved, but drug interaction potential and treatment complexity increase
Solution Approach 1:
The patent combines multiple antiretroviral agents into a single fixed-dose combination tablet containing darunavir, cobicistat, emtricitabine, and tenofovir alafenamide. This merging approach maintains the therapeutic effectiveness of combination therapy while simplifying the treatment regimen to one pill taken once daily, thereby reducing drug interaction potential and improving patient adherence
Solution Approach 2:
The single tablet formulation serves multiple functions simultaneously: it provides protease inhibition (darunavir), pharmacokinetic enhancement (cobicistat), and nucleoside reverse transcriptase inhibition (emtricitabine and tenofovir alafenamide). This multi-functionality allows the unified regimen to address HIV replication through multiple mechanisms while simplifying administration
2Adaptability or versatility
If multiple different drugs are used to suppress HIV and treat other conditions, then comprehensive treatment coverage is improved, but drug interaction risk increases
Solution Approach 1:
The patent merges four different antiretroviral mechanisms into a single fixed-dose combination product, providing comprehensive HIV treatment coverage while reducing the number of separate medications patients must take. This consolidation minimizes opportunities for drug-drug interactions while maintaining broad therapeutic coverage for HIV suppression
3Reliability
If frequent administration is required to maintain drug exposure, then viral suppression reliability is improved, but patient adherence becomes more difficult
Solution Approach 1:
The fixed-dose combination tablet is designed for once-daily administration, establishing a simple periodic dosing schedule that maintains adequate drug exposure levels. This single daily dose regimen improves patient adherence compared to multiple daily doses while continuing to provide reliable viral suppression through sustained pharmacokinetic coverage
Solution Approach 2:
By combining multiple antiretroviral agents with different pharmacokinetic profiles into a single once-daily fixed-dose combination tablet, the patent achieves comprehensive viral suppression reliability through unified administration. The synergistic combination maintains effective drug levels throughout the dosing interval while simplifying the administration schedule to improve adherence
Data Source
AI summary
The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.